Total Payments
$2.0M
2024 Payments
$264,471
Companies
39
Transactions
2,467
Medicare Patients
2,460
Medicare Billing
$682,649
Payment Breakdown by Category
Other$1.7M (81.8%)
Travel$192,711 (9.4%)
Consulting$119,797 (5.9%)
Food & Beverage$54,163 (2.6%)
Research$4,800 (0.2%)
Gifts$20.00 (0.0%)
Education$6.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 599 | 77.6% |
| Travel and Lodging | $192,711 | 758 | 9.4% |
| Consulting Fee | $119,797 | 34 | 5.9% |
| Honoraria | $87,328 | 43 | 4.3% |
| Food and Beverage | $54,163 | 1,030 | 2.6% |
| Unspecified | $4,800 | 1 | 0.2% |
| Gift | $20.00 | 1 | 0.0% |
| Education | $6.09 | 1 | 0.0% |
Payments by Type
General
$2.0M
2,466 transactions
Research
$4,800
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $969,037 | 1,060 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $433,669 | 369 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $129,508 | 186 | $0 (2022) |
| Tris Pharma Inc | $94,911 | 151 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $68,930 | 69 | $0 (2017) |
| Neurocrine Biosciences, Inc. | $63,927 | 101 | $0 (2022) |
| Neos Therapeutics, LP | $63,801 | 90 | $0 (2020) |
| ITI, Inc. | $44,000 | 54 | $0 (2023) |
| Shire North American Group Inc | $40,289 | 61 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $36,539 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $264,471 | 246 | Otsuka America Pharmaceutical, Inc. ($140,566) |
| 2023 | $246,648 | 252 | Otsuka America Pharmaceutical, Inc. ($154,268) |
| 2022 | $207,059 | 224 | Otsuka America Pharmaceutical, Inc. ($151,046) |
| 2021 | $107,009 | 126 | Otsuka America Pharmaceutical, Inc. ($63,632) |
| 2020 | $114,816 | 182 | Otsuka America Pharmaceutical, Inc. ($51,806) |
| 2019 | $315,381 | 414 | Otsuka America Pharmaceutical, Inc. ($110,325) |
| 2018 | $382,037 | 486 | Otsuka America Pharmaceutical, Inc. ($145,507) |
| 2017 | $407,263 | 537 | Otsuka America Pharmaceutical, Inc. ($151,887) |
All Payment Transactions
2,467 individual payment records from CMS Open Payments — Page 1 of 99
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $554.00 | General |
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $7,753.00 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $6.36 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,808.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $21.48 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $796.04 | General |
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $249.66 | General |
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $55.49 | General |
| 11/13/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/13/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $342.95 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/13/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $127.85 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/13/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/05/2024 | Supernus Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $37.21 | General |
| 11/01/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Travel and Lodging | Cash or cash equivalent | $50.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Travel and Lodging | Cash or cash equivalent | $34.29 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Travel and Lodging | Cash or cash equivalent | $17.97 | General |
| Category: PSYCHIATRY | ||||||
| 10/16/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug), REJOYN | Food and Beverage | In-kind items and services | $76.29 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Honoraria | Cash or cash equivalent | $3,552.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Travel and Lodging | Cash or cash equivalent | $536.63 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Travel and Lodging | Cash or cash equivalent | $347.16 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | ABILIFY MAINTENA (Drug) | Food and Beverage | Cash or cash equivalent | $79.29 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-035 | ACADIA Pharmaceuticals Inc | $4,800 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 927 | 4,357 | $595,805 | $241,786 |
| 2022 | 5 | 443 | 2,507 | $350,880 | $127,034 |
| 2021 | 6 | 551 | 2,883 | $417,215 | $154,991 |
| 2020 | 7 | 539 | 2,969 | $419,685 | $158,838 |
Total Patients
2,460
Total Services
12,716
Medicare Billing
$682,649
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 225 | 1,684 | $252,600 | $101,886 | 40.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 255 | 2,082 | $208,200 | $78,743 | 37.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 228 | 256 | $76,800 | $33,571 | 43.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 114 | 217 | $43,400 | $19,759 | 45.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 57 | 61 | $6,100 | $3,706 | 60.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 31 | $4,805 | $2,209 | 46.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $1,650 | $963.05 | 58.4% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 15 | $2,250 | $950.10 | 42.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 134 | 1,303 | $195,450 | $70,764 | 36.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 130 | 964 | $96,400 | $28,382 | 29.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 121 | 140 | $42,000 | $20,707 | 49.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 66 | $10,230 | $4,597 | 44.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 34 | $6,800 | $2,583 | 38.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 159 | 1,811 | $271,650 | $99,855 | 36.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 149 | 763 | $76,300 | $22,223 | 29.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 131 | 145 | $43,500 | $21,486 | 49.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 113 | $17,515 | $7,797 | 44.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 25 | $5,000 | $1,999 | 40.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 26 | $3,250 | $1,631 | 50.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 146 | 2,103 | $315,450 | $117,603 | 37.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 120 | 540 | $54,000 | $16,396 | 30.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 115 | 129 | $19,350 | $9,861 | 51.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 34 | 67 | $10,385 | $4,707 | 45.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 75 | 78 | $7,800 | $4,432 | 56.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 23 | 23 | $6,900 | $3,679 | 53.3% |
About Dr. Matthew Brams, M.D
Dr. Matthew Brams, M.D is a Child & Adolescent Psychiatry healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639187263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Brams, M.D has received a total of $2.0M in payments from pharmaceutical and medical device companies, with $264,471 received in 2024. These payments were reported across 2,467 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
As a Medicare-enrolled provider, Brams has provided services to 2,460 Medicare beneficiaries, totaling 12,716 services with total Medicare billing of $682,649. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Houston, TX
- Active Since 08/03/2006
- Last Updated 06/05/2013
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639187263
Products in Payments
- ABILIFY MAINTENA (Drug) $518,769
- REXULTI (Drug) $426,156
- AUSTEDO (Drug) $296,272
- LATUDA (Drug) $124,325
- Austedo XR (Drug) $92,349
- Dyanavel XR (Drug) $91,664
- Trintellix (Drug) $86,585
- INGREZZA (Drug) $63,927
- Adzenys XR-ODT (Drug) $63,714
- CAPLYTA (Drug) $44,000
- MYDAYIS (Drug) $39,887
- UZEDY (Drug) $33,169
- ABILIFY ASIMTUFII (Drug) $26,197
- FANAPT (Drug) $22,453
- ABILIFY MYCITE (Drug) $14,966
- SD809-TD (Drug) $10,207
- VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) $6,674
- JORNAY PM (Drug) $5,525
- NUPLAZID (Drug) $4,876
- SILENOR (Drug) $4,623
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Houston
Dr. Alice Mao, Md, MD
Child & Adolescent Psychiatry — Payments: $1.1M
Child & Adolescent Psychiatry $1.1M
Dr. Peter Ly, M.d, M.D
Child & Adolescent Psychiatry — Payments: $13,221
Child & Adolescent Psychiatry $13,221
Dr. Jay Tarnow, Md, MD
Child & Adolescent Psychiatry — Payments: $6,230
Child & Adolescent Psychiatry $6,230
Dr. Ann Marie Menendez-Caldwell, M.d, M.D
Child & Adolescent Psychiatry — Payments: $5,661
Child & Adolescent Psychiatry $5,661
Dr. Monica Grover, Md, MD
Child & Adolescent Psychiatry — Payments: $5,573
Child & Adolescent Psychiatry $5,573
Kay Lewis, M.d, M.D
Child & Adolescent Psychiatry — Payments: $4,622
Child & Adolescent Psychiatry $4,622